2/13/2020 7:02:09 AM
Alkermes Plc Q4 Loss Per Share $0.03; Non-GAAP EPS $0.83
1/28/2020 7:01:53 AM
Alkermes Says FDA Accepts ALKS 3831 NDA For Review For Treatment Of Schizophrenia And Bipolar I Disorder
11/25/2019 7:01:14 AM
Alkermes Completes Acquisition Of Rodin Therapeutics
11/19/2019 7:01:43 AM
Alkermes Submits NDA To FDA For ALKS 3831 For Treatment Of Schizophrenia And Bipolar I Disorder
11/18/2019 7:01:38 AM
Alkermes To Acquire Rodin Therapeutics; Expects To Complete Transaction By The End Of November
11/12/2019 7:02:09 AM
Alkermes Receives $150 Mln Milestone Payment From Biogen Triggered By Recent FDA Approval Of VUMERITY
11/8/2019 7:03:01 AM
Alkermes Announces New Data From ALKS 4230 Clinical Development Program At SITC Annual Meeting
10/30/2019 7:31:19 AM
Biogen And Alkermes Announce FDA Approval Of VUMERITY For Multiple Sclerosis
10/23/2019 7:02:06 AM
Alkermes Q3 GAAP Loss/Shr $0.34 And Non-GAAP Loss/Shr $0.04